ArticleCost effectiveness and resource allocation : C/E2025

Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis.

Yu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.